Graham Myfanwy, Eden Edward, Maddison Kelsey, Lago Luise, Allingham Samuel, Lucas Catherine J, Schneider Jennifer, Martin Jennifer H
Australian Centre for Cannabinoid Clinical and Research Excellence, Newcastle, New South Wales, Australia.
Centre for Drug Repurposing and Medicines Research, School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia.
Neuropsychopharmacol Rep. 2025 Mar;45(1):e12498. doi: 10.1002/npr2.12498. Epub 2024 Nov 17.
An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.
A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.
Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.
The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.
2018年1月至2022年6月期间，新南威尔士州政府资助了一项创新的全州大麻药物咨询服务（CMAS）。该服务提供全面的针对患者的循证信息，以支持卫生专业人员进行处方和患者护理决策。本研究旨在描述CMAS收集的真实世界数据。
使用R版本4.2.1对2021年1月至2022年6月期间收集的一组去识别化的、针对患者的咨询（n = 123/567；21.7%）进行分析。使用《监管活动医学词典》（MedDRA）术语对诊断、适应症和合并症进行编码。
来自医生的大多数针对患者的咨询来自全科医生（n = 103/123；83.7%）。女性患者（n = 53/123；43.1%）和男性患者（n = 59/123；48.0%）的比例相近。8.9%（n = 11/123）的患者未注明性别。患者的平均年龄为52.1岁（范围<10 - 90岁）。最常见的三种诊断是骨关节炎、焦虑症和慢性疼痛。最常报告的适应症包括慢性疼痛、焦虑症、背痛、非神经性疼痛和失眠。合并用药最常见的是非阿片类和阿片类镇痛药以及抗抑郁药。大多数医生正在考虑为其患者开具大麻二酚（CBD）产品。CMAS提供的大麻素成分选择指导主要是（δ-9-四氢大麻酚）THC:CBD约为1:1，其次是仅含CBD的产品。卫生专业人员就五名患者潜在不良事件的管理与CMAS进行了联系。
本研究的结果揭示了医生为其关于医用大麻的临床决策寻求信息的情况，并可为临床指导资源的开发提供参考。
